WO1998023574A1 - Asiatic acid derivatives and medicines for treating wounds, which contains the same - Google Patents
Asiatic acid derivatives and medicines for treating wounds, which contains the same Download PDFInfo
- Publication number
- WO1998023574A1 WO1998023574A1 PCT/KR1997/000239 KR9700239W WO9823574A1 WO 1998023574 A1 WO1998023574 A1 WO 1998023574A1 KR 9700239 W KR9700239 W KR 9700239W WO 9823574 A1 WO9823574 A1 WO 9823574A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- group
- compound
- asiatic acid
- yield
- nmr
- Prior art date
Links
- 0 C[C@]1[C@](C)C2C3=CCC([C@@](C)(C[C@@]4O)C(CC5)[C@](C)(COC(C)=O)[C@@]4OC(C)=O)[C@]5(C)[C@]3(C)CC[C@@]2(*)CC1 Chemical compound C[C@]1[C@](C)C2C3=CCC([C@@](C)(C[C@@]4O)C(CC5)[C@](C)(COC(C)=O)[C@@]4OC(C)=O)[C@]5(C)[C@]3(C)CC[C@@]2(*)CC1 0.000 description 2
- NVTZKGZZKLZPCB-VKMLPVGISA-N C[C@@H](CCC1)C2C3=CCC([C@@](C)(C[C@H]4O)C(CC5)[C@@]6(C)[C@H]4OCOC6)[C@]5(C)[C@]3(C)CC[C@@]12C(O)=O Chemical compound C[C@@H](CCC1)C2C3=CCC([C@@](C)(C[C@H]4O)C(CC5)[C@@]6(C)[C@H]4OCOC6)[C@]5(C)[C@]3(C)CC[C@@]12C(O)=O NVTZKGZZKLZPCB-VKMLPVGISA-N 0.000 description 1
- NPCNNWYCAKNOLY-IPTMXWGHSA-N C[C@@H](CCC1)C2C3=CCC([C@@](C)(C[C@H]4O)C(CC5)[C@](C)(CO)[C@H]4O)[C@]5(C)[C@]3(C)CC[C@@]12C(O)=O Chemical compound C[C@@H](CCC1)C2C3=CCC([C@@](C)(C[C@H]4O)C(CC5)[C@](C)(CO)[C@H]4O)[C@]5(C)[C@]3(C)CC[C@@]12C(O)=O NPCNNWYCAKNOLY-IPTMXWGHSA-N 0.000 description 1
- XSEAHDNVIFMMHA-WJQDSBFZSA-N C[C@H](CC1)[C@H](C)C2C3=CCC([C@@](C)(CC4=O)C(CC5)[C@@]6(C)[C@H]4OCOC6)[C@]5(C)[C@]3(C)CC[C@@]12C(O)=O Chemical compound C[C@H](CC1)[C@H](C)C2C3=CCC([C@@](C)(CC4=O)C(CC5)[C@@]6(C)[C@H]4OCOC6)[C@]5(C)[C@]3(C)CC[C@@]12C(O)=O XSEAHDNVIFMMHA-WJQDSBFZSA-N 0.000 description 1
- OCKPHHNPBFJQMS-GINBCCHESA-N C[C@H](CC1)[C@H](C)C2C3=CCC([C@]4(C)C(CC5)C(C)(C)[C@H]6O[C@H]6C4)[C@]5(C)[C@]3(C)CC[C@@]12C(OC)=O Chemical compound C[C@H](CC1)[C@H](C)C2C3=CCC([C@]4(C)C(CC5)C(C)(C)[C@H]6O[C@H]6C4)[C@]5(C)[C@]3(C)CC[C@@]12C(OC)=O OCKPHHNPBFJQMS-GINBCCHESA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J53/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton has been modified by condensation with a carbocyclic rings or by formation of an additional ring by means of a direct link between two ring carbon atoms, including carboxyclic rings fused to the cyclopenta(a)hydrophenanthrene skeleton are included in this class
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D319/00—Heterocyclic compounds containing six-membered rings having two oxygen atoms as the only ring hetero atoms
- C07D319/04—1,3-Dioxanes; Hydrogenated 1,3-dioxanes
- C07D319/08—1,3-Dioxanes; Hydrogenated 1,3-dioxanes condensed with carbocyclic rings or ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C62/00—Compounds having carboxyl groups bound to carbon atoms of rings other than six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
- C07C62/30—Unsaturated compounds
- C07C62/32—Unsaturated compounds containing hydroxy or O-metal groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D303/00—Compounds containing three-membered rings having one oxygen atom as the only ring hetero atom
- C07D303/02—Compounds containing oxirane rings
- C07D303/04—Compounds containing oxirane rings containing only hydrogen and carbon atoms in addition to the ring oxygen atoms
- C07D303/06—Compounds containing oxirane rings containing only hydrogen and carbon atoms in addition to the ring oxygen atoms in which the oxirane rings are condensed with a carbocyclic ring system having three or more relevant rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J61/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton has been modified by contraction of only one ring by one or two atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2603/00—Systems containing at least three condensed rings
Definitions
- the present invention relates to asiatic acid derivatives represented by following chemical formula 1 :
- Ri represents hydrogen, hydroxy group which may be protected by acetyl or benzyl group, methanesulfonyloxy, (methylthio) thiocarbonyloxy, halogen, ethoxymethyloxy or octyloxymethyloxy group
- R 2 represents hydrogen or hydroxy group
- K ⁇ and R 2 may form an oxo group
- R 3 represents hydrogen or hydroxy group which may be protected by acetyl or benzoyl group
- R 2 and R 3 may form an epoxy group
- R 4 represents hydroxymethyl group which may be protected by acetyl or benzoyl group
- R 3 and j may form -OC(R6)(R7)OCH 2 - [wherein, R t is hydrogen, a lower alkyl group having 1 to 4 carbon atoms, or phenyl group, R 7 represents hydrogen, a lower alkyl group having 1 to 4 carbon atoms or phenyl group, and R_s and R 7 may form -(CH
- the extracts including asiatic acid and asiaticoside from Centella asiatica have been used for treatment of hurted skin or chronic ulcer since old times, and also for treatment deformation of skin due to tuberculosis or leprosy [P.
- the present inventors have synthesized various asiatic acid derivatives, starting from asiatic acid obtained from Centella asiatica. They also found that the derivatives have excellent effect for treating wound and completed the present invention.
- the present invention relates to asiatic acid derivatives represented by following formula 1 ,
- R 2 represents hydrogen or hydroxy group which may be protected by acetyl or benzyl group, methanesulfonyloxy, (methylthio) thiocarbonyloxy, halogen, ethoxymethyloxy or octyloxymethyloxy group
- R 2 represents hydrogen or hydroxy group
- RI and R 2 may form an oxo group
- R 3 represents hydrogen or hydroxy group which may be protected by acetyl or benzoyl group
- R 2 and R 3 may form an epoxy group
- R4 represents hydroxymethyl group which may be protected by acetyl or benzoyl group
- R 3 and R4 may form -OC(R6)(R7)OCH 2 - [wherein, R ⁇ is hydrogen, a lower alkyl group having 1 to 4 carbon atoms, or phenyl group, R 7 represents hydrogen, a lower alkyl group having 1 to 4 carbon atoms or phenyl group, and Rt and R 7 may form -(CH 2
- the hydroxy group at 2-position of compound (4) obtained above is treated with sodium hydride and imidazole, to be converted to alkoxide group. Carbon disulfide is added thereto and the mixture is heated under reflux, and then treated with methyl iodide to obtain a xanthate (7).
- the resultant compound is treated with tributyltin hydride and catalytic amount of AIBN to give methyl 2-deoxy-3,23-0-isopropylidene asiatate (8), which is then deprotected to obtain methyl 2-deoxyasiatate (9).
- the compound (9) above is hydrolyzed to obtain 2-deoxyasiatic acid (10).
- Methyl 2-0-octyloxymethyl-3,23-0-isopropylidene asiatate (13) is synthesized by means of Method 2 from compound (4) obtained above . [See Scheme 4.]
- the asiatic acid derivatives according to the present invention exhibited comparable to or more excellent effect than that of control agent, 1% quantitative extract of Centella asiatica (TECA).
- TECA Centella asiatica
- the dose of compound of general formula (1) is 10 to 100 mg/day for an adult.
- the dose usually depends on age and body weight of a patient, as well as the condition of symptoms.
- the medicine for treating wound according to the present invention may be formulated into an ointment by means of conventional methods.
- the extract (62 g) was dissolved in methanol (700 ml), and 5N sodium hydroxide solution(50ml) was added thereto, and the resultant mixture was heated under reflux for 10 hours.
- the reaction mixture was concentrated under reduced pressure, neutralized, filtered and dried to obtain a mixture (2, 43g) of asiatic acid and madecassic acid.
- Example 2 Preparation of 3,23-O-Isopropylidene asiatic acid (3)
- the mixture (12 g) of asiatic acid and madecassic acid, and p- toluenesulfonic acid (200 mg) were dissolved in anhydrous DMF (100 ml), and 2,2-dimethoxypropane (5 ml) was added thereto by injection.
- Mass (El) m/e 542 (M + ), 527 (M + -Me), 482 (M + -HCOOME), 483, 467, 451, 407, 262, 203, 189, 133
- Example 10 Preparation of 2-deoxy-3, 23-O-isopropylidene asiatic acid (11) Excepting from substituting compound 10 for the mixture of asiatic acid and madecassic acid, the same procedure as Example 2 was performed (yield:59.9%).
- Example 5® above the same procedure as Example 5® was performed (yield:53.9%).
- Example 5® Excepting from substituting compound 11 for compound 5 in Example 5® and substituting chloromethylethyl ether for chloromethyloctyl ether, the same procedure as Example 5® was performed (yield:46%).
- Example 5® Excepting from substituting compound 4 for compound 5 in Example 5®, the same procedure as Example 5® was performed.
- Example 5® Excepting from substituting compound 3 for compound 5 in Example 5® and substituting chloromethylmethyl ether for chloromethyloctyl ether, the same procedure as Example 5® was performed (yield: 19%). mp. 104-1121C
- Example 5® Excepting from substituting compound 3 for compound 5 in Example 5® and substituting chloromethylethyl ether for chloromethyloctyl ether, the same procedure as Example 5® was performed (yield :46%).
- Example 5® Excepting from substituting compound 3 for compound 5 in Example 5® and substituting methoxyethoxymethyl chloride for chloromethyloctyl ether, the same procedure as Example 5® was performed (yield:25%). mp. 76-79 ° C
- Example 5® Excepting from substituting compound 3 for compound 5 obtained in Example 5® and substituting chloromethylbenzyl ether for chloromethyloctyl ether , the same procedure as Example 5® was performed and then synthesized through acetylization (yield:45%).
- Example 5® Except from substituting compound 22 for compound 5 used in Example 5®, the same procedure as Example 5® was performed(yield : 44%).
- the asiatic acid derivative (200 mg) according to the present invention was accurately weighed and placed in a 20 ml syringe.
- Propylene glycol (6 g), glycol stearate (3 g) and white petrolatum (1 g) were accurately weighed and added thereto.
- the content of the syringe was completely melted in a water bath at 80 ° C , and stirred for about 5 minutes so that the active component could be homogeneously dispersed in three kinds of vehicles mentioned above.
- purified water (10g) warmed to 80 ° C was placed in another syringe.
- the above two syringes were connected by a threeway connector, and injecting from both side was repeated about 20 times to homogenize the content.
- the homogenized content was put into a vessel and slowly solidified at room temperature.
- the asiatic acid derivatives according to the present invention showed excellent effect on treating wound.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dermatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Steroid Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
Claims
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP97913517A EP0971873A1 (en) | 1996-11-27 | 1997-11-27 | Asiatic acid derivatives and medicines for treating wounds, which contains the same |
JP52455298A JP2001506598A (en) | 1996-11-27 | 1997-11-27 | Asiatic acid derivative and wound treating agent containing the same |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1996/58175 | 1996-11-27 | ||
KR19960058175 | 1996-11-27 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO1998023574A1 true WO1998023574A1 (en) | 1998-06-04 |
WO1998023574A8 WO1998023574A8 (en) | 1999-05-20 |
Family
ID=19483855
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/KR1997/000239 WO1998023574A1 (en) | 1996-11-27 | 1997-11-27 | Asiatic acid derivatives and medicines for treating wounds, which contains the same |
Country Status (5)
Country | Link |
---|---|
EP (1) | EP0971873A1 (en) |
JP (1) | JP2001506598A (en) |
KR (1) | KR19980042831A (en) |
CN (1) | CN1238756A (en) |
WO (1) | WO1998023574A1 (en) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2000063148A1 (en) * | 1999-04-21 | 2000-10-26 | Euphar Group S.R.L. | Salts of asiatic and madecassic acid suitable for the preparation of pharmaceutical and cosmetic compositions |
US6274559B1 (en) * | 1997-02-28 | 2001-08-14 | Dong Kook Pharmaceutical Co., Ltd. | Liver protection or treatment agents comprising asiatic acid derivatives as the active component |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102391351B (en) * | 2011-11-03 | 2013-06-19 | 沈阳化工大学 | Asiatic acid modifier with anti-tumor activity and preparation method of the same |
CN103816164B (en) * | 2014-01-26 | 2015-07-08 | 中国人民解放军第二军医大学 | Application of asiatic acid derivative A1 in preparation of anti-depression drug |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH06329590A (en) * | 1993-05-24 | 1994-11-29 | Kobe Steel Ltd | Triterpene compound, its production and cancer inhibition agent |
WO1996017819A1 (en) * | 1994-12-03 | 1996-06-13 | Dong Kook Pharmaceutical Co., Ltd. | Asiatic acid derivatives, its manufacturing method and dermatological agent containing it |
-
1997
- 1997-11-27 WO PCT/KR1997/000239 patent/WO1998023574A1/en not_active Application Discontinuation
- 1997-11-27 KR KR1019970063417A patent/KR19980042831A/en not_active Application Discontinuation
- 1997-11-27 JP JP52455298A patent/JP2001506598A/en active Pending
- 1997-11-27 CN CN97180161A patent/CN1238756A/en active Pending
- 1997-11-27 EP EP97913517A patent/EP0971873A1/en not_active Withdrawn
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH06329590A (en) * | 1993-05-24 | 1994-11-29 | Kobe Steel Ltd | Triterpene compound, its production and cancer inhibition agent |
WO1996017819A1 (en) * | 1994-12-03 | 1996-06-13 | Dong Kook Pharmaceutical Co., Ltd. | Asiatic acid derivatives, its manufacturing method and dermatological agent containing it |
Non-Patent Citations (7)
Title |
---|
CHEMICAL ABSTRACTS, Vol. 100, No. 21, 21 May 1984, (Columbus, Ohio, USA), page 353, Abstract No. 171516k, J. SAKAKIBARA et al., "Terpenoids of Rhododendron Japonicum"; & PHYTOCHEMISTRY, 1983, 22(11), 2535-5. * |
CHEMICAL ABSTRACTS, Vol. 102, No. 7, 18 February 1985, (Columbus, Ohio, USA), page 351, Abstract No. 59349y, T. KIKUCHI et al., "Studies on the Constituents of Medicinal and Related Plants in Sri Lanka. I. New Triterpenes from Hedyotis Lawsoniae"; & CHEM. PHARM. BULL., 1984, 32(10), 3906-11. * |
CHEMICAL ABSTRACTS, Vol. 109, No. 15, 10 October 1998, (Columbus, Ohio, USA), page 390, Abstract No. 125856j, C. HUANG et al., "Isolation and Identification of Two New Triterpenes from Actinidia Eriantha"; & YUNNAN ZHIWU YANJIU, 1988, 10(1), 93-100. * |
CHEMICAL ABSTRACTS, Vol. 118, No. 21, 24 May 1993, (Columbus, Ohio, USA), pages 536-537, Abstract No. 209385d, C. HUANG et al., "Isolation and Identification of a New Triterpene from Actinidia Eriantha Benth."; & TIANRAN CHANWU YANJIU YU KAIFA, 1992, 4(3), 27-30. * |
CHEMICAL ABSTRACTS, Vol. 122, No. 15, 10 April 1995, (Columbus, Ohio, USA), page 874, Abstract No. 185527f, N. OKADA et al., "A Triterpene, Its Manufacture and Cancer Inhibitors Containing Triterpenes"; & JP,A,06 329 590. * |
CHEMICAL ABSTRACTS, Vol. 125, No. 7, 12 August 1996, (Columbus, Ohio, USA), page 706, Abstract No. 81911x, C. FOURNEAU et al., "Triterpenes from Prunus Africana Bark"; & PHYTOCHEMISTRY, 1996, 42(5), 1391-1393. * |
CHEMICAL ABSTRACTS, Vol. 76, No. 9, 28 February 1982, (Columbus, Ohio, USA), page 2, Abstract No. 41801z, L.F. CHASSEAUD et al., "Metabolism of Asiatic Acid, Madecassic Acid and Asiaticoside in the Rat"; & ARZNEIM.-FORSCHUNG, 1971, 21(9), 1379-84. * |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6274559B1 (en) * | 1997-02-28 | 2001-08-14 | Dong Kook Pharmaceutical Co., Ltd. | Liver protection or treatment agents comprising asiatic acid derivatives as the active component |
WO2000063148A1 (en) * | 1999-04-21 | 2000-10-26 | Euphar Group S.R.L. | Salts of asiatic and madecassic acid suitable for the preparation of pharmaceutical and cosmetic compositions |
AU776202B2 (en) * | 1999-04-21 | 2004-09-02 | Euphar Group S.R.L. | Salts of asiatic and madecassic acid suitable for the preparation of pharmaceutical and cosmetic compositions |
US6891063B1 (en) | 1999-04-21 | 2005-05-10 | Euphar Group S.R.L. | Salts of asiatic and madecassic acid suitable for the preparation of pharmaceutical and cosmetic compositions |
Also Published As
Publication number | Publication date |
---|---|
CN1238756A (en) | 1999-12-15 |
JP2001506598A (en) | 2001-05-22 |
WO1998023574A8 (en) | 1999-05-20 |
KR19980042831A (en) | 1998-08-17 |
EP0971873A1 (en) | 2000-01-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US5834437A (en) | Asiatic acid derivatives its manufacturing method and dermatological agent containing it | |
EP0185359A2 (en) | Oxetanone | |
DE2423155A1 (en) | 5-OXA-PROSTAGLANDIN AND METHOD FOR MANUFACTURING THEREOF | |
GB1599863A (en) | Pharmaceutical compositions for use in the inhibition of the biosynthesis of mevalonic acid | |
DE60312029T2 (en) | PROCESS FOR PREPARING C-7 SUBSTITUTED 5-ANDROSTENDS | |
US4588530A (en) | Anti-inflammatory prednisolone steroids | |
US6169112B1 (en) | Medicines for treating dementia or cognitive disorder, which comprises asiatic acid derivatives | |
DE2460990A1 (en) | NEW PROSTAGLANDIN ANALOGS AND PROCEDURES FOR THEIR PRODUCTION | |
WO1998023574A1 (en) | Asiatic acid derivatives and medicines for treating wounds, which contains the same | |
EP0051558B1 (en) | Prostacyclin derivatives, their preparation and their use in drugs | |
JPS59139400A (en) | Steroid derivative with antialdosteronic activity | |
KR100530278B1 (en) | Liver protection and therapeutic agent with asiatic acid derivative | |
DE2719901A1 (en) | PGE AND 11-DEOXY-PGE COMPOUNDS WITH A METHYLENE GROUP ON THE C-9 | |
DE69126622T2 (en) | 2BETA, 19-METHYLENAMINE BRIDGED STEROIDS AS A AROMATASE INHIBITORS | |
US4331663A (en) | 4α,5α-Epoxy-3,20-dioxopregnane-2α,16α-dicarbonitrile and intermediates and process for preparation, method of use and compositions thereof | |
DE3621024A1 (en) | 11 beta -Phenyloestrenes and -oestradienes, their preparation and pharmaceutical products containing these | |
DE2606051A1 (en) | 2,2-DIFLUORO-PROSTAGLANDIN-E, -F LOW ALPHA, -F LOW BETA, -A AND -B ANALOGA AND METHOD FOR THEIR PRODUCTION | |
DE2542686A1 (en) | 2A, 2B-DIHOMO-15-METHYL- AND -15- AETHYL-PGF AND PGE COMPOUNDS AND METHODS OF PREPARATION | |
LV11954B (en) | 14-ALFA, 17-ALFA-C2-BRACKET 19-NOR-PROGESTERON DERIVATIVES | |
EP0815120A1 (en) | 17-difluoromethylene-oestratrienes | |
DD143912A5 (en) | PROCESS FOR CONSTRUCTION OF THE HYDROXYACETYL SIDE CHAIN OF PREGNAN TYPE STEROIDS | |
RU2255090C2 (en) | Steroid compounds, method for selective modification, pharmaceutical composition | |
JPH0222071B2 (en) | ||
KR100325268B1 (en) | Process for producing asiatic acid | |
Chinn et al. | 9, 11-Seco steroids. Attempt to separate biological activities via ring cleavage |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 97180161.4 Country of ref document: CN |
|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): CN JP US |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
AK | Designated states |
Kind code of ref document: C1 Designated state(s): CN JP US |
|
AL | Designated countries for regional patents |
Kind code of ref document: C1 Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE |
|
CFP | Corrected version of a pamphlet front page | ||
CR1 | Correction of entry in section i | ||
WWE | Wipo information: entry into national phase |
Ref document number: 09308827 Country of ref document: US |
|
ENP | Entry into the national phase |
Ref document number: 1998 524552 Country of ref document: JP Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1997913517 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 1997913517 Country of ref document: EP |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 1997913517 Country of ref document: EP |